Sulindac
Sulindac · SULINDAC 200 mg/1 · Tablet · Actavis Pharma, Inc.
NDC 00591-5660-00 · 29000 TABLET in 1 BAG · DRUG FOR FURTHER PROCESSING · View full market →
Bulk ingredient — not a finished product
This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 42806-0011-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
sole-source market · price up 4% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Sulindac (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | SULINDAC 200 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Actavis Pharma, Inc. | SULINDAC 150 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| PD-Rx Pharmaceuticals, Inc. | SULINDAC 200 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Epic Pharma, LLC | SULINDAC 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Epic Pharma, LLC | SULINDAC 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| PD-Rx Pharmaceuticals, Inc. | SULINDAC 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Proficient Rx LP | SULINDAC 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| PuraCap Laboratories LLC dba Blu Pharmaceuticals | SULINDAC 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| PuraCap Laboratories LLC dba Blu Pharmaceuticals | SULINDAC 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | SULINDAC 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | SULINDAC 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Actavis Pharma, Inc. | SULINDAC 200 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
| Major Pharmaceuticals | SULINDAC 200 mg/1 | Jul 15, 2026 | Jul 29, 2026 |
| Major Pharmaceuticals | SULINDAC 150 mg/1 | Jul 15, 2026 | Jul 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Sulindac — NDC 00591-5660-00," retrieved September 3, 2026, https://drugdashboards.com/drug/00591566000.
Free to cite with attribution — see how the data is put together.